Eissa et al.'s review[
1] warmly invites readers into the often-overlooked realm of isolated asthenozoospermia (iASZ), a condition marked by reduced sperm motility that affects 16%–24% of male infertility cases. With a nod to the authors’ dedication, this work masterfully compiles insights into the physiological, genetic, and molecular underpinnings of iASZ, offering a clear guide to its etiology, diagnosis, and management. By exploring sperm structure, biochemical regulators like calcium, and advanced diagnostics such as genetic screening and electron microscopy, the review paves the way for more targeted approaches to help couples achieve their dreams of parenthood.
Recent advancements have shed light on potential molecular underpinnings of iASZ. For instance, the identification of the
COQ9 gene as a marker involved in mitochondrial function and energy metabolism offers promising avenues for understanding the etiology of reduced sperm motility[
2]. Additionally, the regulatory role of long non-coding RNAs, such as Linc00893, has been implicated in sperm motility, suggesting that epigenetic factors may play a pivotal role in iASZ[
3].
Therapeutically, innovative approaches are emerging. Photobiomodulation therapy using near-infrared light has demonstrated potential in enhancing sperm motility by improving mitochondrial energetic metabolism without inducing oxidative stress[
4]. Moreover, the impact of gut microbiota on sperm quality is gaining attention, with studies indicating that dysbiosis may adversely affect sperm motility, highlighting the intricate interplay between systemic health and reproductive function[
5].
Eissa et al. have offered more than just a literature summary—they've issued a call to action for researchers and clinicians alike to reframe how we understand and manage sperm motility disorders. As precision medicine evolves, iASZ must no longer be a forgotten phenotype, but rather a focal point in the quest to restore male fertility.
PDF
(65KB)
